Search Results - "Segui Palmer, M. A."

Infiltrating ductal carcinoma: infiltrates at the exit site of a central venous access port device by Moya Horno, I., Fernández Morales, L.A., Dalmau Portulas, E., Seguí Palmer, M.A., Font Renom, J., Aparicio Rodríguez, O., Falcó Fages, J., Querol Niñerola, R., Pampols Felip, M., Saigí Grau, E.

Get full text

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology by Pollán, M., Casla-Barrio, S., Alfaro, J., Esteban, C., Segui-Palmer, M. A., Lucia, A., Martín, M.

“…Due to improvements in the number of cancer survivors and survival time, there is a growing interest in healthy behaviors, such as physical activity (PA), and…”
Get full text

Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens by Marin Alcala, M., Llort Pursals, G., Del Riego Ferrari, J.H., Giner, J., Andreu Navarro, F.X., Medina, S., Aparicio, O., Dalmau Portulas, E., Ribera Fernandez, P., Oliveres, H., Martinez Vila, C., Cabrera Romero, J.M., Segui Palmer, M.A., Fernandez Morales, L.A.

Get full text

SEOM clinical guidelines in advanced and recurrent breast cancer (2018) by Chacón López-Muñiz, J. I., de la Cruz Merino, L., Gavilá Gregori, J., Martínez Dueñas, E., Oliveira, M., Seguí Palmer, M. A., Álvarez López, I., Antolin Novoa, S., Bellet Ezquerra, M., López-Tarruella Cobo, S.

“…Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall…”
Get full text

New clinical trials regulation in Spain: analysis of royal decree 1090/2015 by Martin Jimenez, M., Calvo Ferrandiz, A., Aparicio Urtasun, J., Garcia-Campelo, R., Gonzalez-Flores, E., Lazaro Quintela, M., Muñoz Mateu, M., Rodriguez Sanchez, C. A., Santaballa Bertran, A., Sepulveda Sanchez, J. M., Vera Garcia, R., Virizuela Echaburu, J. A., Segui Palmer, M. A.

“…The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform…”
Get full text

Predicting response and survival in chemotherapy-treated triple-negative breast cancer by Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E

“…Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer…”
Get full text

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours by Durán, I., Garzón, C., Sánchez, A., García-Carbonero, I., Pérez-Gracia, J. L., Seguí-Palmer, M. Á., Wei, R., Restovic, G., Gasquet, J. A., Gutiérrez, L.

“…Purpose To estimate the cost per skeletal-related event (SRE) in patients with bone metastases secondary to solid tumours in the Spanish healthcare setting…”
Get full text

Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis by Germá Lluch, J R, Seguí Palmer, M A, Climent Durán, M A, Blanco Guerrero, R, Fernández Sagarra, A, Villavicencio, H, Solé Balcells, F J

“…Forty-one patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) of the testis were treated between 1980 and 1989. This group was defined by the…”
Get more information

230PComplete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens by Marin Alcala, M, Llort Pursals, G, Del Riego Ferrari, J H, Giner, J, Andreu Navarro, F X, Medina, S, Aparicio, O, Dalmau Portulas, E, Ribera Fernandez, P, Oliveres, H, Martinez Vila, C, Cabrera Romero, J M, Segui Palmer, M A, Fernandez Morales, L A

Get full text

Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status by Fernandez-Morales, L. A., Dalmau, E., Martinez, S., Arcusa, A., Pericay, C., Lain, J. M., Font, J., Tortajada, L., Saigi, E., Segui-Palmer, M. A.

“…Abstract only 626 Background: The determination of ER and PR has a considerable importance when evaluating the prognosis and the response to treatment in…”
Get full text

Analysis of the pathological response to primary chemotherapy, using news and classics biomolecular factors, in patients with locally advanced breast cancer (LABC) by Segui-Palmer, M. A., Fernandez-Morales, L. A., Arcusa, A., Pericay, C., Saez, A., Andreu, X., Florensa, R., Font, J., Lain, J. M., Saigi, E.

“…Abstract only…”
Get full text

Association between bone turnover markers and skeletal-related events in patients with breast cancer and bone metastases on treatment with bisphosphonates: ZOMAR study results at nine months of follow-up by Barnadas, A., De la Piedra, C., Crespo, C., Gomez Pardo, P., Calvo, L., Calvo, E. G., Ruiz-Borrego, M., Rifa, J., Manso, L., Anton, A., Codes, M., Margeli, M., Murias, A., Salvador, J., Seguí-Palmer, M. A., De Juan, A., Gavila, J., Perez, D., Luque, M., Tusquets, I.

“…Abstract only…”
Get full text

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC) by Dieras, V., Jassem, J., Dirix, L. Y., Guastalla, J. P., Bono, P., Hurvitz, S. A., Gonçalves, A., Romieu, G., Limentani, S. A., Jerusalem, G. H. M., Lakshmaiah, K., Roche, H. H., Sánchez-Rovira, P., Pienkowski, T., Seguí-Palmer, M. A., Li, A., Sun, Y., Pickett-Gies, C. A., Wildiers, H.

“…Abstract only…”
Get full text

Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer by Martín-Jiménez, Miguel, Rodríguez-Lescure, Álvaro, Ruiz-Borrego, Manuel, Seguí-Palmer, Miguel-Ángel, Brosa-Riestra, Max

“…Introduction The randomised controlled trial BCIRG001 has recently demonstrated that docetaxel in combination with doxorubicin and cyclophosphamide (TAC) has…”
Get full text

Infiltrating ductal carcinoma: infiltrates at the exit site of a central venous access port device by Moya Horno, I, Fernández Morales, L A, Dalmau Portulas, E, Seguí Palmer, M A, Font Renom, J, Aparicio Rodríguez, O, Falcó Fages, J, Querol Niñerola, R, Pampols Felip, M, Saigí Grau, E

Get full text

Follow-up of patients with localized germinal testicular tumors: 6 years' experience at the "Santa Creu i Sant Pau" Hospital by Climent Duran, M A, Germa Lluch, J R, Seguí Palmer, M A, Fernández Sagarra, A, Izquierdo Delso, M A, Lacasta Muñoa, A

“…From 1984 to 1989, 89 patients with stage I testicular carcinoma had been treated and followed at the Oncology Unit of the "Santa Creu i Sant Pau" Hospital…”
Get more information

The clinico-mammographic follow-up of breast cancer after conservative treatment by Climent Durán, M A, Gómez Gómez, A, Seguí Palmer, M A, Blanco Guerrero, R, De Marco Izquierdo, J A, Rueda Domínguez, A, Fuentes Raspall, J, Ojeda González, B, Alonso Muñoz, M C

“…Clinical and mammographic follow-up of 149 patients diagnosed of stage I and II breast neoplasm and treated with conservative surgery and irradiation between…”
Get more information

Does total androgen suppression in advanced prostatic cancer induce a greater number of complete remissions? A phase II trial by Germà Lluch, J R, Izquierdo Delso, M A, Seguí Palmer, M A, Villavicencio, H, Ojeda González, B, de Andrés Basauri, L, Pallarés Curto, C

“…The present Phase II study's main objective was to evaluate the rate of complete responses (CR) obtained through total androgenic suppression (TAS) in patients…”
Get more information